Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal‐Cell Carcinoma: A Nationwide Cancer Registry Study

[1]  K. Bensalah,et al.  Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[2]  A. Lenis,et al.  Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials , 2018, The Journal of urology.

[3]  D. Boffa,et al.  Using the National Cancer Database for Outcomes Research: A Review , 2017, JAMA oncology.

[4]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[5]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[6]  Steven L. Chang,et al.  Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Plimack,et al.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. , 2016, The Lancet. Oncology.

[8]  S. Giordano,et al.  Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. , 2016, JAMA oncology.

[9]  Ya-Chen Tina Shih,et al.  Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. , 2015, Clinical genitourinary cancer.

[10]  G. Cooper,et al.  The Impact of Delayed Chemotherapy on Its Completion and Survival Outcomes in Stage II Colon Cancer Patients , 2014, PloS one.

[11]  Dae-Ho Lee,et al.  Active surveillance for metastatic or recurrent renal cell carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.

[12]  H. Mukai,et al.  First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma. , 2013, Urology.

[13]  J. Larkin,et al.  Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation , 2012, Front. Oncol..

[14]  C. Sternberg,et al.  Targeted therapies for renal cell carcinoma: review of adverse event management strategies. , 2012, Journal of the National Cancer Institute.

[15]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Chong,et al.  Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma. , 2009, Urologic oncology.

[18]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[19]  M. Cooperberg,et al.  Renal cell cancer stage migration , 2008, Cancer.

[20]  C. Ko,et al.  The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.

[21]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[22]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[23]  K. Maclennan,et al.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.

[24]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Belldegrun,et al.  The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.

[26]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.